HHS Peptide Policy: What Providers Need to Know About 503A Pharmacies and Compounded Peptides

If you offer or plan to offer peptide therapy, the biggest regulatory question of the past three years just got a more workable answer. On October 28, 2026, HHS filed a Federal Register notice announcing an interim enforcement policy for six peptides compounded by 503A pharmacies. It does not make these peptides FDA approved. It does set clear conditions under which HHS does not intend to take enforcement action, and those conditions put heavy weight on where your pharmacy gets its active ingredient.

That is why the 503A pharmacy you choose matters more than the peptide you choose.

What is the HHS peptide enforcement discretion policy?

The policy covers six peptide bulk drug substances while the 503A bulks list is developed through rulemaking. The Pharmacy Compounding Advisory Committee recommended these peptides for inclusion on that list in July 2026. All six had sat in FDA's Category 2 from September 2023 until April 22, 2026, and HHS says neither the placement nor the removal changed their status under section 503A.

HHS states that the goal is to discourage widespread use of research use only peptides from foreign suppliers and give patients a more controlled alternative: peptides compounded by a licensed pharmacy from tested, traceable ingredients. Enforcement discretion is not an approval and it does not add the peptides to the final 503A bulks list. HHS can also revise or withdraw the policy, including if a safety signal or product quality issue appears.

Which compounded peptides does the policy cover?

The policy names six compounded peptides, each limited to a specific form and route of administration:

• BPC-157 peptide (acetate): subcutaneous, intramuscular, oral and topical
• TB-500 peptide (acetate): subcutaneous or intramuscular injection
• Epitalon (acetate): subcutaneous or intramuscular injection, dispensed in intermittent courses
• Semax (free base): intranasal
• KPV peptide (acetate): topical and oral
• MOTS-c (acetate): subcutaneous or intramuscular injection

Only BPC-157 and KPV are covered in oral form. Any other peptide, or any listed peptide outside its listed form and route, falls outside the policy and has to be evaluated on its own under federal compounding rules. Popular peptides that are not on this list are not covered.

Are peptides legal for providers to prescribe?

That depends on how the peptide is made and supplied. Compounded drugs are not FDA approved, and FDA does not review their safety, effectiveness or quality before they are marketed. Under the interim policy, HHS does not intend to take action against a state-licensed pharmacy or licensed physician compounding one of these six peptides when every condition is met. Peptides sold as research peptides, labeled for research use only, are a different story: they are not made for human use and are the exact supply HHS wants to move patients away from.

That is a conditional position, not blanket permission, and it says nothing about whether any peptide is safe or effective for a given patient. Have your own counsel review your state and practice setup.

What does a 503A compounding pharmacy have to do under the policy?

A 503A pharmacy compounds a drug for an individual patient based on a valid, patient-specific prescription. To fall within the policy, the peptide must also meet these conditions:

• Registered source. The active ingredient must come from a facility registered with FDA under section 510. The original manufacturer, not just a repacker or distributor, must follow current good manufacturing practice (CGMP), and its location must appear on the certificate of analysis.
• Certificate of analysis (COA) for every lot. The COA must show testing for identity, purity, potency, and contaminants such as endotoxins, heavy metals and microbial contamination.
• Vendor validation. If the ingredient comes through a repacker or reseller, that company must have validated the original manufacturer and its COA.
• Single active ingredient. The compounded product may contain only one listed peptide, which makes it easier to tie an adverse event to a specific substance.
• Required label statement. "This is a compounded drug product. Not for resale."
• Syringe only. The only device packaged with or containing the drug can be an FDA 510(k)-cleared syringe. Do not assume a cleared injector pen or other device satisfies this.
• Oral bioavailability evidence. For oral forms, the compounder must document that the specific formulation achieves adequate oral bioavailability in humans.
• Reporting. Serious adverse events and product quality issues go to FDA MedWatch and to the relevant states.

Why 503A pharmacy peptides come down to ingredient sourcing

Nearly every condition above comes back to one idea: you should be able to trace what is in the vial to a registered, CGMP-compliant manufacturer, with lot-level testing to prove it. For 503A pharmacy peptides, the pharmacy, not the provider, is the party that has to obtain and document that source. That is the part of a peptide compounding pharmacy relationship you cannot verify from a price list.

Before you prescribe, ask any pharmacy these questions. Can they show the COA for the lot your patient will receive? Do they know and document the original manufacturer and its FDA registration? Do they compound only single-ingredient products? Which route and form do they compound for each peptide? How do they report adverse events? A pharmacy that cannot answer quickly is not one to build a peptide program on.

503A vs 503B: which pharmacies does the policy cover?

The policy is written for 503A compounding: patient-specific prescriptions filled by a state-licensed pharmacy, a federal facility or a licensed physician. 503B outsourcing facilities, which can produce larger batches without individual prescriptions, are not covered. The policy creates no new allowance for a 503B facility to compound these six peptides. So the facility type matters as much as the product.

What this means for peptide therapy clinics, med spas and telehealth

Whether you run a peptide therapy clinic, a med spa adding peptide injections, or a telehealth peptide program, four practical points follow from the policy:

• No blends. Because the compounded product can contain only one active ingredient, combinations of peptides, or a peptide with another drug, do not qualify. Stack and blend products need separate review.
• Labeling and marketing. Never imply that enforcement discretion means FDA approval. Keep the compounded, not FDA approved disclosure on patient-facing pages.
• Platform rules differ. Advertising platforms, payment processors and card brands set their own policies and may update them on a different timeline than HHS. Confirm each one before you advertise or bill for injectable peptides.
• Plan for change. FDA can revise or withdraw the policy, so build your program so you can adjust offerings quickly.

LegitScript, the healthcare certification organization, has said that offering one of these peptides does not by itself bar certification when the offering meets the policy's conditions and all other applicable standards, effective November 2, 2026.

How DrWell supports your peptide therapy program

DrWell works with 503A pharmacy partners so providers can offer peptide therapy through a pharmacy that is accountable for sourcing its active ingredients from FDA-registered manufacturers with a lot-specific COA. DrWell is not a pharmacy and does not practice medicine. Your clinicians make the clinical decisions, and your 503A pharmacy partner handles compounding to the conditions above.

If you are building or expanding a peptide therapy practice, DrWell helps you launch and run the program, from prescribing workflows to patient management, with a pharmacy network built around these standards.

Book a sourcing call with DrWell

Frequently asked questions

Are compounded peptides FDA approved? No. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before marketing. Enforcement discretion does not change that.

Are peptides safe? The policy does not make that finding. HHS built conditions around lot testing, single-ingredient products and adverse event reporting so risks can be tracked, and it can revisit the policy if a safety signal appears. Clinical decisions stay with the prescriber.

What is the 503A bulks list? It is the list of bulk drug substances that can be used in 503A compounding when they are not in a USP monograph or a component of an FDA-approved drug. It is still being developed through rulemaking, and the HHS interim policy covers the gap for these six peptides.

Are oral and injectable peptides both covered? Only within each peptide's listed routes. Injectable forms are covered for BPC-157, TB-500, Epitalon and MOTS-c, oral forms only for BPC-157 and KPV, and Semax only intranasally.

Does this cover 503B outsourcing facilities? No. The policy applies to 503A pharmacies and licensed physician compounders.

What should I ask my pharmacy before prescribing? Nothing, DrWell does the vetting for you! We have COAs (Certificate of Analysis) on file and can confirm all peptides, along with all medications we source from 503A pharmacies come from FDA-registered manufacturers.

Sources: HHS enforcement discretion policy (Appendix B), Federal Register notice, LegitScript analysis

This article is for informational purposes and is not legal or medical advice. Compounded drugs are not FDA approved. Providers should consult their own legal and compliance advisors.

‍